Health Policy & Services

249.3K Papers

Follow See full results

Article Health Policy & Services

Effects of the Indian National Health Insurance Scheme (PM-JAY) on Hospitalizations, Out-of-pocket Expenditures and Catastrophic Expenditures

Divya Parmar, Christoph Strupat, Swati Srivastava, Stephan Brenner, Diletta Parisi, Susanne Ziegler, Rupak Neogi, Caitlin Walsh, Manuela De Allegri

Summary: India has launched a large health insurance program, PM-JAY, which targets economically and socially disadvantaged individuals. This program has led to an increase in the use of private facilities and a reduction in out-of-pocket expenditures for eligible individuals. However, there was no significant increase in hospitalizations.

HEALTH SYSTEMS & REFORM (2023)

Add to Collection

Article Economics

Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

Junxing Chay, Joshua Yi Min Tung, Rebecca Jade Su, Edwin Jonathan Aslim, Callix Wong, Georgia Swan, Wei Jin Chua, Henry Sun Sien Ho, Eric Andrew Finkelstein

Summary: This study evaluated the cost-effectiveness of minimally invasive surgical therapies for moderate-to-severe BPH patients in Singapore, finding that WVTT as a first-line treatment is cost-effective for both moderate and severe patients, while PUL is not cost-effective. TURP is cost-effective as a first-line treatment for severe patients only.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Healthcare costs among patients with newly diagnosed helicobacter pylori infection in the United States: a linked claims-EHR study

Shailja Shah, Katherine Cappell, Robert Sedgley, Corey Pelletier, Rinu Jacob, Machaon Bonafede, Rena Yadlapati

Summary: This study aimed to characterize the cost drivers of patients with Helicobacter pylori (HP) and estimate the cost savings associated with successful eradication compared to failed eradication. The results showed that the healthcare costs of HP patients are influenced by comorbidities and there are significant cost savings for patients with successful HP eradication in specific HP-related conditions.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study

Yan Wang, Weihua Gao, Xu Han, Jenny Jiang, Belinda Sandler, Xiaoyan Li, Carla Zema

Summary: This study used the Optum Market Clarity database to examine the relationship between New York Heart Association (NYHA) functional class and cardiovascular outcomes in obstructive hypertrophic cardiomyopathy (HCM). The study found that as the NYHA class worsened, the risks of all outcomes increased.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Editorial Material Economics

Cost-effectiveness of Left Atrial Appendage Closure with WATCHMAN device for non-valvular atrial fibrillation patients in Japan. Are the policy implications big in Japan?

Panagiotis Petrou

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Health care resource utilization in 3L+patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib

Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Diana Tran, Pearl Wang, Kejal Jadhav, Aurore Yocolly, Koji Sasaki

Summary: This study assessed and compared the health care resource utilization (HCRU) rates of asciminib and bosutinib among 3 L+ patients with chronic myeloid leukemia in chronic phase (CML-CP) in the ASCEMBL trial. The results showed that asciminib-treated patients had lower resource utilization compared to bosutinib-treated patients over the long-term.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

Sasha Berry, Barrie Chubb, Annabel Acs, Edel Falla, Akanksha Verma, Samuel J. P. Malkin, Barnaby Hunt, Andrew J. Palmer

Summary: The study aimed to investigate the performance of the IQVIA Core Diabetes Model in predicting the outcomes of the SUSTAIN 6 trial and examine the impact of calibration on cost-effectiveness outcomes from a UK healthcare payer perspective. The results showed that once-weekly semaglutide had improved health economic benefits in treating diabetes-related complications compared to placebo plus standard of care, especially after calibration.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention

Stephane Alexandre Regnier, Xin Ying Lee

Summary: This study conducted a meta-regression analysis on placebo data from clinical trials of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies for migraine prevention, and found that intravenous administration of placebo led to a higher reduction in monthly migraine days. Additionally, episodic migraine type and a higher proportion of patients with multiple failed preventive treatments were associated with lower efficacy.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Impact of information and deliberation on the consistency of preferences for prioritization in health care - evidence from discrete choice experiments undertaken alongside citizens' juries

Jennifer A. Whitty, Peter Littlejohns, Julie Ratcliffe, Kylie Rixon, Andrew Wilson, Elizabeth Kendall, Paul Burton, Kalipso Chalkidou, Paul A. Scuffham

Summary: This study compared the opinions on prioritizing access to bariatric surgery obtained through a Citizens' Jury (CJ) and a preference elicitation method (Discrete Choice Experiment, DCE). The results showed that the important criteria were similar across the groups, but the order of importance varied. The participants in the CJ had more diverse opinions after deliberation, with a higher priority given to those with comorbidities. This study contributes to understanding the use of different methods for gathering public opinions on healthcare decisions.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand

Warittakorn Kategeaw, Nontaya Nakkam, Sasisopin Kiertiburanakul, Chonlaphat Sukasem, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk

Summary: This study evaluated the cost-effectiveness of HLA-B*13:01 screening before co-trimoxazole initiation in HIV-infected patients in Thailand. The findings suggest that this screening strategy may not be cost-effective.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Correction Economics

Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes (vol 26, pg 935, 2023)

P. Rossing, F. Groehl, P. Mernagh, K. Folkerts, A. Garreta Rufas, J. Harris, K. Meredith, M. Carter, O. Akerborg, C. Wanner, F. D. Richard Hobbs

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Review Economics

Economic burden of respiratory syncytial virus infection in adults: a systematic literature review

Mei Grace, Ann Colosia, Sorrel Wolowacz, Catherine Panozzo, Parinaz Ghaswalla

Summary: This study aims to investigate the economic and healthcare resource utilization burden in older adults due to RSV infection. A total of 42 studies were identified, reporting cost and healthcare resource utilization data associated with RSV infections. Results showed that hospitalization costs were highest in the US. The study highlights the importance of implementing RSV preventive strategies to reduce this burden.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs

Aaron T. T. Gerds, Jingbo Yu, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn Scherber, Shreekant Parasuraman

Summary: This study evaluated healthcare resource utilization, direct costs, and overall survival of Medicare beneficiaries newly diagnosed with myelofibrosis who received ruxolitinib treatment. The study found that patients treated with ruxolitinib had reduced healthcare utilization, decreased medical costs, and increased survival compared to untreated patients.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States

Pengxiang Li, Carmela Benson, Zhi Geng, Sanghyuk Seo, Charmi Patel, Jalpa A. A. Doshi

Summary: This study is the first to examine antipsychotic use, healthcare resource utilization, costs, and quality of care among individuals with schizophrenia in the Medicare program. The results showed low utilization rates of long-acting injectable antipsychotics, high hospital admissions/readmissions, and emergency room visits, with regional variations observed.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Editorial Material Economics

Implementation of technology in healthcare entities - barriers and success factors

Teresa Pakulska, Urszula Religioni

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland

Andrea Favre-Bulle, Goran Bencina, Shujing Zhang, Ruixuan Jiang, Daniel Andritschke, Arjun Bhadhuri

Summary: This study assessed the cost-effectiveness of adjuvant pembrolizumab compared to observation for resected stage IIB/IIC melanoma patients in Switzerland. The results showed that pembrolizumab is highly cost-effective as an adjuvant treatment for these patients.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Letter Economics

Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States

Wei Gao, Arash Mostaghimi, Kavita Gandhi, Nicolae Done, Markqayne Ray, James Signorovitch, Elyse Swallow, Christopher Carley, Travis Wang, Vanja Sikirica

Summary: Limited evidence suggests that medical costs for people with alopecia areata (AA) vary significantly in the absence of effective treatments. This study investigated the factors influencing medical costs for privately insured adults and adolescents with AA in the United States. The study identified middle-aged patients (45-64 years) in the Northeast region, those with comprehensive health insurance, extensive hair loss, or other health disorders as facing higher all-cause medical costs. Adult females in the age groups of 18-44 years and 65+ years also incurred higher costs on average. The research confirms the variability of the burden of AA and highlights population subgroups more affected by the disease and associated disorders.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims-based retrospective cohort study

Tu My To, Jamie T. Ta, Anisha M. Patel, Stella Arndorfer, Ibrahim M. Abbass, Rita Gandhy

Summary: This study quantified healthcare resource utilization and costs for individuals with late-onset Huntington's disease (LoHD), comparing them with adult-onset HD (AoHD) and non-HD controls. The results showed that LoHD patients had significantly higher healthcare burden and costs than non-HD controls, similar to AoHD patients. This highlights the significant healthcare burden associated with LoHD.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

Paulos Gebrehiwet, Lisa Meng, Stacy A. Rudnicki, Phil Sarocco, Jenny Wei, Andrew A. Wolff, Michael Butzner, Adriano Chio, Jinsy A. Andrews, Angela Genge, Dyfrig A. Hughes, Carlayne E. Jackson, Noah Lechtzin, Timothy M. Miller, Jeremy M. Shefner

Summary: This post hoc analysis of the FORTITUDE-ALS study suggests that reldesemtiv showed a modest but significant benefit in health utilities and QALYs compared with placebo in patients with ALS.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States

Manuela Di Fusco, Kinga Marczell, Elizabeth Thoburn, Timothy. L. L. Wiemken, Jingyan Yang, Benjamin Yarnoff

Summary: This study assessed the public health impact and economic value of booster vaccination with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent in the United States. The results showed that compared to no booster vaccination, the Pfizer-BioNTech COVID-19 Vaccine could reduce approximately 3.7 million symptomatic cases, 162 thousand hospitalizations, and 45 thousand deaths, and it was cost-saving.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

«
1
2
3
4
5
»

See full results

Related Categories

Business (271.6K) Business, Finance (171.3K) Demography (30.6K) Economics (636.2K) Hospitality, Leisure, Sport & Tourism (116.8K) Industrial Relations & Labor (31.7K) International Relations (112.5K) Law (212.7K) Operations Research & Management Science (247.1K) Political Science (225.4K) Public Administration (60.2K) Regional & Urban Planning (72.1K) Urban Studies (74.6K)

© Peeref 2019-2024. All rights reserved.